Member Info for cottoner

Symphony bullish on additive

Another day, another Aim company’s shares rocketing as a result of coronavirus.

This time it was the turn of Symphony Environmental, whose d2p plastic additive can destroy 99.84 per cent of bovine coronavirus within 24 hours. Because d2p is embedded in the plastic, it does not require constant wiping down.

Bovine coronavirus is from the same virus family as Covid-19 and Michael Laurier, Symphony’s chief executive, is “pretty sure” that d2p will kill Covid-19 as well.

He has asked the government to free a laboratory for a coronavirus test but this has so far “proved an impossible task”, he said. “All we’re asking for is a few hours in a lab to be able to test [d2p] against coronavirus.” This year US regulators approved d2p’s use in bread bags to kill bacteria. The latest test shows d2p, in the works for a decade, can also kill viruses, which he described as a “very exciting and positive development”.

Mr Laurier said that potential applications were endless, including bank cards, door handles and Tupperware. “Just about everything you can see or touch is where d2p should go.”

The shares leapt 76.7 per cent to 26½p, valuing the company at £45 million.

Article just released on BBC website

Plastic pollution to weigh 1.3 billion tonnes by 2040

An estimated 1.3 billion tonnes of plastic is destined for our environment - both land and water - by 2040, unless global action is taken.

That's according to a global projection of the scale of the problem over the next 20 years.

Dr Costas Velis from the University of Leeds said the number was "staggering" but that we had "the technology and the opportunity to stem the tide".

continues..

https://www.bbc.co.uk/news/science-environment-53521001

Hope not! :-)

AIM
Cancellation - Synnovia Plc
RNS Number : 5423U
AIM
26 November 2019

There'll be more than one winner.

Wrt to releasing news before shares care admitted to AIM.

ORPH is an example of an AIM company where a placing was done , and material RNSes were issued before some of the placing shares were admitted to AIM.

Timeline of ORPH.
22nd May - Fundraising announced. inc date of admission oi fundraising shares of June 12th.

June 4th. OIRPH release RNS announcing launch of COCID-19 Antibodt testing.
June 9th ORPH release RNS detailing Major New contract signed.

Full speed ahead for the Hydrogen Taskforce
Jul 08, 2020

A new cross-industry coalition was unveiled earlier this year aiming to secure a step-change in investment for hydrogen in the UK, across its many applications, in a bid to make the UK a world leader in the applications and services of hydrogen.

Backed by twelve major companies at the heart of the energy system, the Hydrogen Taskforce comprises of Arup, Baxi, BNP Paribas and Arval, BOC, BP, Cadent, DBD, ITM Power, Northern Gas Networks, SGN, Shell and Storengy.

Formerly launched in Parliament at the beginning of March, the Taskforce marked its launch with the publication of a report on The Role of Hydrogen in Delivering Net Zero, which outlined a series of policy recommendations for industry and government to work towards over the next five months.

The action plan included the following steps:

Development of a cross-departmental Hydrogen Strategy within UK Government.
Commitment by government of £1bn over the next Spending Review Period to hydrogen production, storage and distribution projects.
Development of financial support for the production of hydrogen for blending into the gas grid, industrial use, power generation and transport.
Amendment of Gas Safety Management Regulations (GSMR) to enable hydrogen blending into the UK Gas Grid and take the next steps towards 100% hydrogen heating through supporting public trials and mandating hydrogen-ready boilers by 2025.
Collaboration to establish 100 hydrogen refuelling stations by 2025 to support the roll-out of hydrogen transport.

The Taskforce is now preparing to release an Imperial College London-reviewed economic impact assessment on the impact of hydrogen on UK gross value added (GVA) and jobs this August and understands that a major announcement from the UK Government on hydrogen will occur this summer.
.......
https://www.h2-view.com/story/full-speed-ahead-for-the-hydrogen-taskforce/

Currently BUY @ 11.6775 and SELL @ 11.55

Because they won't give me a quote.

None available @ 1.75

At the moment can't buy any online but can sell for 1.74. (halifax)

Currently sell @ 11.85 and buy @ 11.80.

Sealand Capital Galaxy Limited (LSE: SCGL)

Sealand Capital Galaxy Limited (LSE: SCGL)

A little research indicates that the short video market in China looks quite interesting.

Article from April 2020

The short video market in China: Embodies the fast pace of modern life

The little puppy held by your favorite actor on your screen has already provided you a burst of happiness. Conveniently, videos automatically slide endlessly one after the other, displaying content chosen specifically for you by an algorithm. It’s so addictive that you suddenly realize an hour has already passed. The short video market in China is highly sophisticated and widely used, a growing part of the stay-at-home economy in China.

Just like the content on these platforms, the figures of the short video market in China are making heads dizzy. The Coronavirus crisis has shed more light on an already booming industry. A large number of mobile users and the addiction for short video content among Chinese Millennials were already the drivers of the consumption of short video content. This viral trend is reshaping the content market, with short video marketing strategies in China becoming increasingly crucial for marketers.

https://daxueconsulting.com/short-video-market-china/

End of Chairman's letter:

Despite COVID-19 we still remain extremely confident for the future but as a result of the approximate three to four month delay to our business plan caused by COVID-19 we are having to push back our forecasts with a consequential impact on market expectations.

COVID-19 Outbreak Serving as Additional Motivation to Develop Universal Flu Vaccine
June 29, 2020

Much attention has been paid to the race to develop a vaccine that could neutralize COVID-19.

However, even before this pandemic shook up life as we knew it, efforts were reportedly being made to conjure a universal vaccine that could be mobilized in the event of a pandemic flu, which, per the Centers for Disease Control and Prevention (CDC), emerged three times in the 20th century.

In a 2018 article, Axios reported on a claim from the National Security Council that, until the U.S. improves its vaccines, the country would not be ready to confront a flu pandemic (SARS-CoV-2, the virus that causes the disease known as COVID-19, is not a strain of influenza).

If this assertion may have fallen on deaf ears back in 2018, Axios has reported that the COVID-19 outbreak appears to have reinforced the need for a universal flu vaccine that could address a future pandemic flu.

continues...

https://www.verisk.com/insurance/covid-19/iso-insights/covid-19-outbreak-serving-as-additional-motivation-to-develop-universal-flu-vaccine/

typo- obviously 12.1 not 2.1 :-)

For accuracy:

Actually at one point you could sell @ 12.1 aqnd buy for a little less.
SO number of those trades at 12.1 will have been sells.

Currently can still sell @2.1 but no quote to buy online.(Halifax)

The market for NPX002 and NXP004 which are both looking to treat fibrosis diseases has increased marketly because of the after effects of COVID-19.

NFX have the products which they say peerform better than the current treatments available.

Can NFX monetise them?

Dr Karl Keegan has written a book entitled: Biotechnology Valuation

Hopefully he should be well placed.

Coronavirus: Warning thousands could be left with lung damage

Tens of thousands of people will need to be recalled to hospital after a serious Covid-19 infection to check if they have been left with permanent lung damage, doctors have told the BBC.

Experts are concerned a significant proportion could be left with lung scarring, known as pulmonary fibrosis.

The condition is irreversible and symptoms can include severe shortness of breath, coughing and fatigue.

NHS England said it was opening specialist rehabilitation centres.

continues...

https://www.bbc.co.uk/news/health-53065340

As far as I am aware the following is still factually correct:

NXP002

Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme

Data show Nuformix Investigational Candidates (NXP002) outperform current standard of care

Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions

· In addition, NXP002 demonstrated specific action measured against key inflammatory targets

· NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)

NXP004

The Company has commenced pre-clinical pilot studies to investigate the potential for NXP004 as a treatment for multiple forms of fibrosis in various human tissues with its research partner,

Initial data received is very promising and suggests NXP004 has a significantly superior anti-fibrotic action compared to currently approved therapies.